Tetsuya Nosaka

Prof. Tetsuya Nosaka

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2003
Verified
Journal Article
Closed access
TKToshio Kitamura
Toshio Kitamura
YKYuko Koshino
Yuko Koshino
FSFumi Shibata
Fumi Shibata
TOToshihiko Oki
Toshihiko Oki
HNHideaki Nakajima
Hideaki Nakajima
HKHidetoshi Kumagai
Hidetoshi Kumagai

24 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CDCorina N. D’aLessandro-Gabazza
Corina N. D’aLessandro-Gabazza
TKTetsu Kobayashi
Tetsu Kobayashi
TYTaro Yasuma
Taro Yasuma
MTMasaaki Toda
Masaaki Toda
HKHeejin Kim
Heejin Kim
Esteban C. GabazzaEsteban C. Gabazza
Esteban C. Gabazza
Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease of unknown etiology; however, apoptosis of lung alveolar epithelial cells plays a role in disease progression. This intractable disease is associated with increased abundance ofStaphylococcusandStreptococcusin the lungs, yet their roles in disease pathogenesis remain elusive. Here, we report thatStaphylococcus nepalensisreleases corisin, a peptide conserved in diverse staphylococci, to induce apoptosis of lung epithelial cells. The disease in mice exhibits acute exacerbation after intrapulmonary instillation of corisin or after lung infection with corisin-harboringS. nepalensiscompared to untreated mice or mice infected with bacteria lacking corisin. Correspondingly, the lung corisin levels are significantly increased in human IPF patients with acute exacerbation compared to patients without disease exacerbation. Our results suggest that bacteria shedding corisin are involved in acute exacerbation of IPF, yielding insights to the molecular basis for the elevation of staphylococci in pulmonary fibrosis.

23 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CDCorina N. D’aLessandro-Gabazza
Corina N. D’aLessandro-Gabazza
TYTaro Yasuma
Taro Yasuma
TKTetsu Kobayashi
Tetsu Kobayashi
MTMasaaki Toda
Masaaki Toda
AAAhmed Abdel-Hamid
Ahmed Abdel-Hamid
Esteban C. GabazzaEsteban C. Gabazza
Esteban C. Gabazza
Idiopathic pulmonary fibrosis is an incurable disease of unknown etiology. Acute exacerbation of idiopathic pulmonary fibrosis is associated with high mortality. Excessive apoptosis of lung epithelial cells occurs in pulmonary fibrosis acute exacerbation. We recently identified corisin, a proapoptotic peptide that triggers acute exacerbation of pulmonary fibrosis. Here, we provide insights into the mechanism underlying the processing and release of corisin. Furthermore, we demonstrate that an anticorisin monoclonal antibody ameliorates lung fibrosis by significantly inhibiting acute exacerbation in the human transforming growth factorβ1 model and acute lung injury in the bleomycin model. By investigating the impact of the anticorisin monoclonal antibody in a general model of acute lung injury, we further unravel the potential of corisin to impact such diseases. These results underscore the role of corisin in the pathogenesis of acute exacerbation of pulmonary fibrosis and acute lung injury and provide a novel approach to treating this incurable disease.

1 August 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KMKen Murata
Ken Murata
HKHidetoshi Kumagai
Hidetoshi Kumagai
TKToshiyuki Kawashima
Toshiyuki Kawashima
KTKaori Tamitsu
Kaori Tamitsu
MIMariko Irie
Mariko Irie
TKToshio Kitamura
Toshio Kitamura
The receptor tyrosine kinase FLT3 is constitutively activated by an internal tandem duplication (ITD) mutation within the juxtamembrane domain in 20–30% of patients with acute myeloid leukemia. In this study, we identified GTP-14564 as a specific kinase inhibitor for ITD-FLT3 and investigated the molecular basis of its specificity. GTP-14564 inhibited the growth of interleukin-3-independent Ba/F3 expressing ITD-FLT3 at 1 μm, whereas a 30-fold higher concentration of GTP-14564 was required to inhibit FLT3 ligand-dependent growth of Ba/F3 expressing wild type FLT3 (wt-FLT3). However, this inhibitor suppressed the kinase activities of wt-FLT3 and ITD-FLT3 equally, suggesting that the signaling pathways for proliferation differ between wt-FLT3 and ITD-FLT3. Analysis of downstream targets of FLT3 using GTP-14564 revealed STAT5 activation to be essential for growth signaling of ITD-FLT3. In contrast, wt-FLT3 appeared to mainly use the MAPK pathway rather than the STAT5 pathway to transmit a proliferative signal. Further analysis demonstrated that the first two tyrosines in an ITD were critical for STAT5 activation and growth induction but that all of the tyrosines in the juxtamembrane region were dispensable in terms of the proliferation signals of wt-FLT3. These results indicate that an ITD mutation in FLT3 elicits an aberrant STAT5 activation that results in increased sensitivity to GTP-14564. Thus, FLT3-targeted inhibition is an attractive approach, with the potential for selective cytotoxicity, to the treatment of ITD-FLT3-positive acute myeloid leukemia.

1 March 2014 in Vaccine
Verified
Journal Article
Closed access
KWKenta Watanabe
Kenta Watanabe
AMAkihiro Matsubara
Akihiro Matsubara
MKMitsuo Kawano
Mitsuo Kawano
SMSatoru Mizuno
Satoru Mizuno
TOTomotaka Okamura
Tomotaka Okamura
YYYasuhiro Yasutomi
Yasuhiro Yasutomi

1 July 2017 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
RORyoichi Ono
Ryoichi Ono
MMMasahiro Masuya
Masahiro Masuya
SISatomi Ishii
Satomi Ishii
NKNaoyuki Katayama
Naoyuki Katayama
TNTetsuya Nosaka
Tetsuya Nosaka
PLZF is a transcription factor that confers aberrant self-renewal in leukemogenesis, and the PLZF-RARA fusion gene causes acute promyelocytic leukemia (APL) through differentiation block. However, the molecular mechanisms of aberrant self-renewal underlying PLZF-mediated leukemogenesis are poorly understood. To investigate these mechanisms, comprehensive expression profiling of mouse hematopoietic stem/progenitor cells transduced with Plzf was performed, which revealed the involvement of a key transcriptional coactivator, Eya2, a target molecule shared by Plzf and PLZF-RARA, in the aberrant self-renewal. Indeed, PLZF-RARA as well as Plzf rendered those cells immortalized through upregulation of Eya2. Eya2 also led to immortalization without differentiation block, while depletion of Eya2 suppressed clonogenicity in cells immortalized by PLZF-RARA without influence on differentiation and apoptosis. Interestingly, cancer outlier profile analysis of human samples of acute myeloid leukemia (AML) in The Cancer Genome Atlas (TCGA) revealed a subtype of AML that strongly expressed EYA2. In addition, gene set enrichment analysis of human AML samples, including TCGA data, showed that this subtype of AML was more closely associated with the properties of leukemic stem cells in its gene expression signature than other AMLs. Therefore, EYA2 may be a target for molecular therapy in this subtype of AML, including PLZF-RARA APL.